Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Micro Therapeutics

This article was originally published in The Gray Sheet

Executive Summary

Withdraws its 510(k) submission for its Embolyx liquid embolic system for the treatment of arteriovenous malformations (AVMs) and head and neck tumors. The San Clemente, California-based firm, which says it is in discussions with FDA regarding a study design, intends to submit an IDE for further clinical evaluations. Additional studies related to aneurysms and peripheral vascular applications are expected. More than 40 AVM treatment procedures have been performed to date at sites in Los Angeles, Mexico City and Buenos Aires. An additional 10-patient trial to evaluate Embolyx in the pre-operative treatment of hypervascular tumors was recently initiated at UCLA Medical Center



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts